Kidney Transplant Clinical Trials

Clinical trials related to Kidney Transplant Procedure

A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Operationally Seamless Phase 2/3 Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of AIC263029 in the Treatment of BKV Infection in Kidney Transplant Recipients

Status: Recruiting
Location: See all (7) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The goal of this clinical trial is to learn if AIC263029 is safe and well tolerated in adult kidney transplant recipients with BK virus (BKV) in the blood (viremia). The study will also examine how the body processes AIC263029 and whether it lowers BKV levels in the blood. Researchers will compare AIC263029 to a placebo (a look-alike injection with no active drug). Participants will be assigned by chance to receive AIC263029 or placebo and will receive weekly injections under the skin for 4 weeks. Participants will have clinic visits and blood tests during treatment and follow-up to monitor safety and measure BKV levels, and will be followed for up to about 24 weeks after treatment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Male or female aged 18 years or older

• Kidney transplantation within 12 months prior to randomization

• First episode of detectable BKV DNA in plasma since last kidney transplantation. As defined by either:

‣ positive BKV DNA test of one time \>104 IU/mL and \<106 IU/mL, within 30 days prior to randomization, or

⁃ \>103 IU/mL and ≤104 IU/mL sustained for at least 2 weeks (confirmed by at least 2 consecutive measurements), with the most recent measurement within 14 days prior to randomization.

• Female participants (if of childbearing potential) must agree to remain abstinent (refrain from heterosexual intercourse) or use at least one highly effective contraceptive method that result in a failure rate of \<1% per year until the end of the trial.

• Male participants must agree to refrain from donating sperm, and to remain abstinent (refrain from heterosexual intercourse) or use a condom with a female partner of childbearing potential until the end of the trial.

• Negative serum β-HCG (beta-human chorionic gonadotropin) test for women of child-bearing potential at Screening and a negative urine pregnancy test prior to randomization on Day 1.

• Able and willing to provide written informed consent and comply with trial protocol.

Locations
United States
Alabama
University of Alabama at Birmingham Hospital
RECRUITING
Birmingham
Florida
Tampa General Hospital
RECRUITING
Tampa
Georgia
Emory University
RECRUITING
Atlanta
Maryland
University of Maryland Medical Center
RECRUITING
Baltimore
North Carolina
Wake Forest School of Medicine
RECRUITING
Winston-salem
New Jersey
Cooperman Barnabas Medical Center
RECRUITING
Livingston
Ohio
University Hospitals Cleveland Medical Center
RECRUITING
Cleveland
Time Frame
Start Date: 2026-10-05
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 24
Treatments
Experimental: AIC263029
Weekly subcutaneous AIC263029 administered over 4 weeks. Three initial dose cohorts are planned (100 mg, 200 mg, 330 mg), with 5 weekly injections over 4 weeks; within each cohort, participants are randomized 3:1 to AIC263029 vs placebo. Up to 3 additional optional cohorts may be enrolled.
Placebo_comparator: Placebo
Matching placebo administered by subcutaneous injection on the same schedule as active treatment within each cohort
Related Therapeutic Areas
Sponsors
Leads: AiCuris Anti-infective Cures AG

This content was sourced from clinicaltrials.gov